Company Overview and News


Add CTSO
to your dashboard

Headline News

Cytosorbents Corp (CTSO) CEO Phillip Chan Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day everyone and welcome to the CytoSorbents Third Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will being the call – we will open the call for your questions. Please be advised that the call will be recorded as the Company's request. (13-1)

CytoSorbents Introduces The CytoSorb Therapeutic ECMO Kit At The

2017-09-26 devicespace
MONMOUTH JUNCTION, N.J., Sept. 26, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announced the launch and immediate availability of its CytoSorb Therapeutic ECMO Kit, at the 30th Annual European Society of Intensive Care Medicine (ESICM) Congress in Vienna, Austria (September 23-27, 2017). (15-0)

CytoSorbents Release: Key Clinical Study Showing Reversal Of Refractory Septic Shock In Patients Treated With CytoSorb

2017-09-26 devicespace
MONMOUTH JUNCTION, N.J., Sept. 25, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ill and cardiac surgery patients around the world, highlighted the recent publication of a study entitled "Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study" in the Journal of Artificial Organs. (15-0)

CytoSorbents Introduces the CytoSorb Therapeutic ECMO™ Kit at the 2017 European Society of Intensive Care Medicine Congress

2017-09-26 prnewswire
MONMOUTH JUNCTION, N.J., Sept. 26, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ill and cardiac surgery patients around the world, announced the launch and immediate availability of its CytoSorb Therapeutic ECMO™ Kit, at the 30th Annual European Society of Intensive Care Medicine (ESICM) Congress in Vienna, Austria (September 23-27, 2017). (15-0)

Key Clinical Study Showing Reversal of Refractory Septic Shock in Patients Treated with CytoSorb®

2017-09-25 prnewswire
MONMOUTH JUNCTION, N.J., Sept. 25, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically ill and cardiac surgery patients around the world, highlighted the recent publication of a study entitled "Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study" in the Journal of Artificial Organs. (15-0)

CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients

2017-08-14 devicespace
MONMOUTH JUNCTION, N.J., Aug. 14, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that it has been awarded a grant from the U.S. Army Medical Research and Materiel Command to develop new blood purification therapies to acutely stabilize victims of severe burn injury.  This work aligns with the Combat Casualty Care Research Program burn injury task area of the Forward Surgical En Route and Critical Care research portfolio.

CytoSorbents Awarded $719,000 Grant To Acutely Stabilize Severe Burn Patients

2017-08-14 prnewswire
MONMOUTH JUNCTION, N.J., Aug. 14, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, announced that it has been awarded a grant from the U.S. Army Medical Research and Materiel Command to develop new blood purification therapies to acutely stabilize victims of severe burn injury.  This work aligns with the Combat Casualty Care Research Program burn injury task area of the Forward Surgical En Route and Critical Care research portfolio.

CytoSorbents' (CTSO) CEO Dr. Phillip Chan on Q2 2017 Results - Earnings Call Transcript

2017-08-08 seekingalpha
Good day everyone and welcome to the CytoSorbents Second Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded as the Company's request.

Why CytoSorbents And Spectral Medical Inc Are Not Good Stocks For A Long Position

2017-08-04 seekingalpha
CytoSorbents and Spectral Medical Inc. are two medical device companies that have much in common. One is based in US and the other in Canada. CytoSorbents is in the business of reducing ICU deaths from fatal inflammation. Spectral Medical Inc. is in the business of treating sepsis, “life-threatening organ dysfunction caused by a dysregulated host response to infection.”, which is the leading cause of ICU deaths globally.

CytoSorbents To Report Q2 2017 Operating and Financial Results

2017-08-01 devicespace
MONMOUTH JUNCTION, N.J., Aug. 1, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO),  CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report Q2 2017 financial results after the market close on Monday, August 7, 2017. 

CytoSorbents Expands Distribution And Sales of CytoSorb To Treat Deadly Inflammation In Panama With DRGR

2017-07-17 devicespace
MONMOUTH JUNCTION, N.J., July 17, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using CytoSorb® blood purification to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that it has partnered with Droguería Ramón González Revilla (DRGR) to expand the sales and distribution of this life-saving technology to Panama.

CytoSorbents Awarded $1 Million STTR Phase II Contract To Advance Development of Life-Saving Universal Plasma

2017-07-13 prnewswire
MONMOUTH JUNCTION, N.J., July 13, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy specializing in blood purification, today announced that it has been awarded a Small Business Technology Transfer (STTR) Phase II contract, valued at a total of $999,070 over two years, to continue development of blood purification technologies designed to enable "universal" plasma.

CUSIP: 23283X206